News

Professor Heonyong Park at FNUSA-ICRC

17. 9. 2019 | 

Professor Heonyong Park came to visit The International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) at the invitation of the Molecular control of cell signaling team. Prof. Park works in the Department of Molecular Biology at the Institute of Biotechnology and Nanosensors of Dankook University. In addition to a tour of the laboratories at the Biopark, he also gave a public lecture entitled The Pharmaceutical Mechanism of Action on FAK-Assoicated Drug in the Vascular System.

On this occasion we asked him about his impressions of the visit.

You were in the Czech Republic for the first time? How did you like it in Brno?
I visited Brno, Czech Republic for the first time. It was very impressive that people in Brno were very kind, delightful and cheerful. Therefore, I was thinking that Brno was the place where people love to live. In addition, I have known that Gregor Johann Mendel had studied and made his genetics discoveries in Brno.

What are your impressions of the FNUSA-ICRC visit?
I thought that FNUSA-ICRC was the excellent research center where researchers  actively exchange their opinions and I also noticed that FNUSA-ICRC laboratories were well equipped with state-of-the-art technologies. This is important for professors and PIs who also need more researchers to work in order to achieve better results using fully theirresources. Wonderful to me.

Have you discussed any possibilities of cooperation with Brno colleagues in the future?
Yes, it was discussed with Brno colleagues regarding various topics. Especially, I was interested in cell adhesion linked to inflammation and cancer, while I discussed with Brno colleagues. More specifically, I will collaborate with Dr Shin, because our research interests are very similar.

Professor Heonyong Park
heart surface

16. 9. 2019 | 

We have been awarded a joint U.S. patent with Mayo Clinic for systems and methods for epicardial pacing, ablation, and defibrillation. Epicardial “outer” heart surface is often crucial for treatment of arrhythmias but cannot not be reached by standard venous or arterial access. Thus, percutaneous techniques were developed using novel devices, as manipulation vastly differs. Our Interventional Cardiac Electrophysiology research team (ICE) and Electrophyiology group at Mayo Clinic developed specific tools – sheaths and catheters, for novel methods of pacing ablation and defibrillation in pericardial space.

The method is reserved for patients with pericardial location of arrhythmic sources and pathways, possibly also patients after cardiosurgery, requiring specific pacing and eventually defibrillation (e.g. pediatric patients and adult parents with depression of systolic function).

ICE team has been conducting device testing and optimization since 2011. Its leader Zdeněk Stárek led experiments taking place in our Electrophysiology lab at Veterinary and Pharmaceutical University. Both stimulation and defibrillation required much less than currently used energy (e.g. allowing new battery strategies). Moreover, lower utilized energies of ICD defibrillation (Implantable Cardioverter Defibrillator), will presumably result in absence much lesser pain in case patient is conscious during shock delivery.

Epicardial “outer” heart surface
prof. Christian Hengstenberg and prof. Julia Mascherbauer at FNUSA-ICRC

12. 9. 2019 | 

Following last year's visit of the Heads of Cardiology Research Teams of the International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) at the University of Medicine and the General Hospital in Vienna Prof. Christian Hengstenberg - Head of the Department of Cardiology and his colleague Professor Julia Mascherbauer - Head of the Department of Cardiovascular Magnetic Resonance, arrived on September 11.

The visit to the laboratories of cardiology research teams was followed by public lectures. Professor Hengstenberg spoke about his experience with Transcatheter Aortic Valve Implantation (TAVI) in a lecture entitled Modern Therapy of Valvular Heart Disease. Professor Mascherbauer followed up with a presentation entitled Mitral and Tricuspid Valves.

One of the points of the visit program was also the establishment of cooperation between the 1st Department of Internal Cardio-angiology (I. IKAK) of the of St. Anne's University Hospital Brno in Brno and the Clinic of Cardiology of the General Hospital in Vienna. “Cooperation with the workplace in Vienna seems to be very promising for us,” added prof. MUDr. Lenka Špinarová, Ph.D, FESC, head of I. IKAK.

Prof. Christian Hengstenberg and Professor Julia Mascherbauer  at FNUSA-ICRC
NY Times Cover Page

11. 9. 2019

Úvodní strana New York Times

With a little exaggeration, it could be written like that. Information that the scientists from the International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) contributed significantly to research that has shown that dog owners are healthier than the rest of the population, most Czech media have taken over.

Now the report has been published by Mayo Clinic scientists in their Mayo Clinic Proceedings magazine, and US news sites have also shown great interest in this information. Brno was thus mentioned in such influential and well-known American media as CNN television, the New York Times, or the Newsweek weekly. See the list of media channels below:

CNN: https://edition.cnn.com/2019/08/23/health/dog-study-heart-healthy-trnd/index.html
New York Times https://www.nytimes.com/2019/08/26/well/family/dogs-cats-pets-heart-health.html
NewsWeek https://www.newsweek.com/owning-dog-boost-heart-health-scientists-1455648
New York Post https://nypost.com/2019/08/23/want-a-healthy-heart-get-a-dog-study-suggests/

Thanks to Kardiovize Brno 2030 group for spreading awareness about our city!

ICoLA 2019 Logo

9. 9. 2019 |

ICoLA 2019

Cardiovascular experts met in the capital of the Republic of Korea for three days. For the eighth time, the International Congress of Lipids and Atherosclerosis (ICoLA 2019) was attended by nearly a thousand delegates and fifty exhibiting companies. It was a unique opportunity to exchange scientific knowledge on cardiometabolic risk, to share knowledge and research results through active discussions, and to network with one another.

The International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) was actively represented by Manlio Vinciguerra, head of the research team Epigenetics, Metabolism and Aging. "I spoke at a blood pressure symposium with a presentation on Anti-hypertensive Effects of FMD (Fasting Mimicking Diet) and Cardiovascular Disease on Friday," added Manlio Vinciguerra. "On Saturday I chaired an interesting session on Air Pollution and Cardiovascular Disease.”

Let's just add that the Fast Mimicking Diet is called an imitation of a five-day fast. It is a low-calorie five-day diet program designed to promote weight loss and provide the same benefits as traditional fasting methods. Several clinical studies have shown that in addition to weight loss, it also lowers blood sugar, cholesterol, and helps with inflammatory problems.
 

The International Human Peroxidase Meeting  Brno

6. 9. 2019 | 

The International Human Peroxidase Meeting is now taking place in Brno. It is the world's most important event for mammalian peroxidase researchers and its role in human health or disease identification. The meeting is organized by the The International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) together with the Institute of Biophysics of the Academy of Sciences of the Czech Republic and the Universität für Bodenkultur Wien (BOKU).

Peroxidases are a large group of enzymes that play a role in various biological processes. "This conference focuses mainly on myeloperoxidase, eosinophil peroxidase, lactoperoxidase, thyroid peroxidase, peroxidazines 1 & 2, therefore heme peroxidase in mammals," confirmed Lukáš Kubala, head of the FNUSA-ICRC research team Inflammation. "The topics will cover both the molecular enzymology, physiology and pathophysiology of peroxidases, the chemistry and biochemistry of oxidation products, and the function of peroxidases in host defense and tissue biology."

Participators were welcomed also by Christine Winterbourn, a world-renowned legend in the field. She came to Brno from the University of Otago (New Zealand), where she is a professor of pathology. She was one of the first scientists to prove that human cells produce free radicals as part of their normal function and have documented some of the free radical chemical reactions that occur in diseases such as cancer, stroke, ischemic heart disease or arthritis. As the first woman in history she has received the Rutherford Medal, the most prestigious scientific award in New Zealand.

Christine Winterbourn in Brno, University in Otago
Go to top